Great Expectations for Personalized Medicine Outside Oncology | Diaceutics

Great Expectations for Personalized Medicine Outside Oncology

June 21st, 2016

Peter Keeling
Steve Vitale

We are all familiar with personalized medicine in oncology but future developments involving new technologies are likely to flourish in other disease areas. Peter Keeling and Steve Vitale of Diaceutics look at challenges and opportunities in the non-oncology space.

Oncology has always been the front runner in personalized medicine so this is where targeted therapies and diagnostics have, for the most part, been focused. However, there is new and exciting activity outside this area where biomarker and targeted approaches are proving successful.

There are now biomarker-driven therapies for diabetes and inflammatory diseases (such as asthma and rheumatoid arthritis) and neurological diseases (such as Alzheimer’s, Parkinson’s and multiple sclerosis). The total number of targeted drugs in this space has doubled in five years and while oncology still dominates as the single most important therapy area, development in other disease areas has increased exponentially.

Diagnostics in oncology tend to be linked to specific therapies based on single analyte detection (by PCR, FISH, IHC, etc.) from tumor or blood samples. Outside oncology, however, there will be multiple entry points for biomarkers that are not necessarily blood-based. Depending on the disease area there is a set of potential new diagnostic tools, such as wearables, that can be employed singly or in combination, making the non-oncology space a more complicated but competitive landscape. These tools may ultimately be employed to differentiate certain brands, drive faster regulatory approval and/or improve the value proposition presented to payers and patients.

Is the future already here?
Pharma is already gearing up for a non-oncology future, as demonstrated by a sharp increase in personalized medicine deals outside on oncology since 2011 (Figure 1). Deals between pharma and diagnostic or lab partners have started to converge in both spaces. This is why Diaceutics anticipates that non-oncology could be equally, if not more, as active as oncology. But there could be a change in the volume and nature of the agreements that pharma have with external partners in this space. Additionally, the focus of such agreements, which is towards technology partnering, may change, as shown by Novartis and Microsoft teaming up to further develop Kinect for multiple sclerosis (MS) assessment2.

a380fbfc34744f74af6fbf9f07f13f9d

Figure 1. Deals among 14 leading pharma companies (*biomarker discovery, companion/complementary diagnostic development).1

All this activity around partnering mirrors Diaceutics’ own experience as 50 per cent of our expertise has been built by working on personalized medicine challenges outside oncology. Since 2005, Diaceutics has completed multiple projects focused solely on non-oncology issues: broad, diagnostic, testing and lab strategies in HIV, Alzheimer’s, insulin resistance, sepsis, hepatitis C and neglected diseases such as TB and leprosy, plus financial modelling for rheumatoid arthritis, to name just a few. This demonstrates just how much development is already taking place outside oncology.

Expect to see a diverse testing landscape outside oncology
In MS, the gold standard for diagnosis is imaging, but there is significant work being done on biomarkers to identify patients, or measure therapeutic response to pharmaceutical interventions. Stratify JCV was developed to address a significant safety issue for a specific therapy, but many companies are trying to identify a prognosis biomarker to identify and track disease progression. In addition, sensitive wearable technologies can gather data on daily movement and motion to inform the clinical perspective. Clinical trials reveal substantial activity in this area, while health apps and devices are expanding from the consumer field into the diagnostic world.

Another area where we can expect to see a rise in the use of diagnostics is at opportune points early on the treatment pathway. In rheumatoid arthritis, for example, big issues restrict biologics to a small patient pool in the very late stages of the disease, when damage to the joints has already been done. But research shows that earlier identification and treatment can reduce joint damage and improve quality of life3. By identifying inflection points on the pathway, and incorporating existing and novel biomarkers, is it possible to create a perfect storm of diagnostic, education and novel therapy to get earlier treatment to the right patients that also benefits cost-management?

Collaboration with payers on this last point could provide the incentive to make sure tests are used as early as possible and have rapid uptake.

b59fe93ea28b40d4a7929365ba35eaa6

Non-oncology personalized medicine: a risky bet but a potential winner
The non-oncology space is more complex, potentially more expensive and risky, but get it right and there are significant access, market and patient share benefits. It is likely that pharma companies will start to craft a diagnostic entry into treatment pathways where they hold valuable assets. This could impact on product uptake, peak sales, access and pricing discussions, because there is a strong correlation between the choice of test, particularly early in the treatment pathway, and the potential to avoid costly outcomes later.

Personalized medicine in oncology has been a euphemism for high priced targeted therapies but this is not sustainable as a model outside where there is a much larger population. For instance, a new test in NSCLC could be used up to 80,000 times in its first year, but in cardiology or CNS we would need to add a few zeros to that figure.

Competitors in key disease areas are lining up some very interesting multi-test strategies. As a result, ‘one size fits all’ therapies will increasingly be competing with test-enabled therapies, and 2017 will be a key tipping point.

This article was published in Life Science Leader on 1 September 2016. http://www.lifescienceleader.com/doc/great-expectations-for-personalized-medicine-outside-oncology-0001

References

  1. Diaceutics Pharma PM Readiness Report 2016
  2. http://mobihealthnews.com/content/microsoft-novartis-partner-kinect-based-multiple-sclerosis-assessment-tool
  3. Rheum Dis Clin North Am. 2005 Nov;31(4):745-62
  4. Webinar – Personalized Medicine: What Are the Up and Coming Therapeutic Areas in Non-Oncology

Blogs

View all blogs

Webinars & Podcasts

August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
April 20th, 2018
Podcast: PM Readiness Report 2018
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Case Studies

View all case studies

Publications

September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
August 3rd, 2018
A Way Forward: Leveraging Advanced Diagnostic Testing to Unlock the Value of Precision Medicine
Read about how advanced diagnostic testing, ensuring that right patient gets the right therapy, at the right time, particularly with respect to therapies where the test result determines whether or not the therapy should be used (precision medicin...
View all publications
Facebook
Twitter
YouTube
LinkedIn